Adam Taich Sells 15,098 Shares of 10x Genomics (NASDAQ:TXG) Stock

Posted by on May 29th, 2026

10x Genomics (NASDAQ:TXG – Get Free Report) CFO Adam Taich sold 15,098 shares of 10x Genomics stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $24.44, for a total transaction of $368,995.12. Following the completion of the transaction, the chief financial officer owned 379,898 shares of the company’s stock, valued at $9,284,707.12. The trade was a 3.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

10x Genomics Stock Up 9.7%

TXG opened at $27.99 on Friday. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -164.65 and a beta of 2.05. The firm has a 50-day moving average price of $22.23 and a 200-day moving average price of $19.98. 10x Genomics has a twelve month low of $8.81 and a twelve month high of $28.17.

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.19. The firm had revenue of $150.84 million during the quarter, compared to the consensus estimate of $146.41 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.28) earnings per share. On average, sell-side analysts expect that 10x Genomics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 10x Genomics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. purchased a new stake in 10x Genomics during the 4th quarter valued at $38,000. Larson Financial Group LLC boosted its position in 10x Genomics by 164.4% during the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares during the period. Fifth Third Bancorp bought a new position in 10x Genomics in the 1st quarter worth $50,000. Van ECK Associates Corp raised its holdings in 10x Genomics by 85.9% in the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after purchasing an additional 1,695 shares in the last quarter. Finally, Abich Financial Wealth Management LLC bought a new position in 10x Genomics in the 3rd quarter worth $56,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Stifel Nicolaus boosted their price objective on shares of 10x Genomics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Citigroup boosted their price objective on shares of 10x Genomics from $18.00 to $24.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. UBS Group boosted their price objective on shares of 10x Genomics from $14.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. Canaccord Genuity Group increased their price objective on 10x Genomics from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Finally, Zacks Research downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $23.17.

View Our Latest Report on TXG

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.

Featured Stories

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.